| Chapter 1 Effects of Conbercept on Type 1 macular neovascularization with three types of pigment epithelial detachment in nAMDObjective To observe the efficacy of intravitreal injection of Conbercept(IVC)in the treatment of Type 1 macular neovascularization(MNV)with 3 types of pigment epithelial detachment(PED)in neovascular age-related macular degeneration(nAMD).Methods Retrospective clinical research.42 eyes of 42 patients with the disease diagnosed in the Central Theater General Hospital from June 2018 to June 2021 were included in the study.All eyes received 3 monthly consecutive IVC treatment,and subsequent re-treatments were evaluated and administered as needed.According to the characteristics of PED on optical coherence tomography(OCT),the eyes were divided into three groups:serous PED(sPED),fibrovascular PED(fPED)and hemorrhagic PED(hPED).Each eye underwent routine ophthalmological examinations such as best corrected visual acuity(BCVA),and OCT was used to measure macular foveal thickness(CFT)and the degree of regression of PED(height,area and volume).The visual function and anatomical outcomes of three groups were compared at baseline and 3,6,and 12 months after treatment.Results There were 16(38.1%),14(33.3%)and 12 eyes(28.6%)in the three groups of sPED,fPED and hPED,respectively.The reduction of height,area and volum were-119.31±224.13 μm,-0.86±5.00 μm2 and-0.56±1.64 μm3,respectively in sPED group;-53.93±92.51 μm,-0.76±2.54 μm,and-0.19±0.46 μm3,respectively in fPED group;-318.67±258.09 μm,-6.54±6.33 μm,and-1.95±1.78 μm3,respectively in hPED group between baseline and the 12 months.At the 12 months,there were significant differences in the reduction of 3 parameters between the three groups(P<0.05).The reduction of 3 parameters in hPED group was significantly larger than other two groups(P<0.05).BCVA and CFT were significantly improved between baseline and the 12 months in the fPED and hPED groups(P<0.05).No significant difference was determined in the sPED group(P>0.05).At the 12 months,there was no significant difference in the changement of visual acuity between the three groups(P>0.05).Conclusion Conbercept can effectively improve or stabilize the visual function and anatomical structure of Type 1 MNV with 3 types of PED in nAMD.Moreover,conbercept has the better anatomical outcome on HPED.Chapter 2 The effects of Conbercept and Ranibizumab on Type 1 macular neovascularization with fibrovascular pigment epithelial detachment in nAMDObjective To compare the efficacy of intravitreal injection of conbercept and ranibizumab in the treatment of Type 1 macular neovascularization(MNV)with fibrovascular pigment epithelial detachment.(fPED)in neovascular age-related macular degeneration(nAMD).Methods Retrospective clinical study.A total of 48 patients with 48 eyes of the disease diagnosed in our hospital in 2019-11/2021-11 were included,and they were divided into two groups:conbercept and ranibizumab according to the drugs they received.All eyes received monthly,3 consecutive intravitreal injections followed by additional doses as needed(3+PRN).Each eye received routine ophthalmic examinations such as best corrected visual acuity(BCVA),and optical coherence tomography(OCT)was used to measure the foveal thickness(CFT)and the degree of regression(height,area,volume)of retinal pigment epithelial detachment(PED).Visual and anatomical outcomes were compared between the two groups at baseline and at 3,6,and 12 months after treatment.Results There were 26(54.2%)and 22(45.8%)eyes in the conbercept and ranibizumab groups,respectively.There were no significant differences of visual acuity,CFT,PED height,area and volume in the baseline between the two groups(P>0.05).The BCVA of the two groups was no significant improvement between the baseline and the follow-up period(P>0.05).Compared with the baseline,the CFT of the conbercept group was significantly improved at 3,6 and 12 months after treatment(Ftime=6.065,P<0.05),however,the CFT of the ranibizumab group was only significantly improved at 3 month(Ftime=6.065,P<0.05).The PED height of the two groups was significantly improved at 3,6 and 12 months after treatment compared with the baseline(Ftime=6.686,P<0.05).The PED area and volume were not significantly improved(P>0.05).No significant differences was determined in BCVA,CFT,PED height,area and volume between the two groups during the follow-up period(P>0.05).Conclusion In this case series,conbercept and ranibizumab have good effects on type 1 MNV with fPED in nAMD,which can reduce the PED height and CFT,and stabilize the visual acuity,PED area and volume.However,conbercept can achieve longer reduction of macular edema. |
PDF Full Text Request